JP2014515354A - Osw−1類似体および抱合体、ならびにそれらの使用 - Google Patents

Osw−1類似体および抱合体、ならびにそれらの使用 Download PDF

Info

Publication number
JP2014515354A
JP2014515354A JP2014511580A JP2014511580A JP2014515354A JP 2014515354 A JP2014515354 A JP 2014515354A JP 2014511580 A JP2014511580 A JP 2014511580A JP 2014511580 A JP2014511580 A JP 2014511580A JP 2014515354 A JP2014515354 A JP 2014515354A
Authority
JP
Japan
Prior art keywords
certain embodiments
group
compound according
aforementioned compounds
osbp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014511580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515354A5 (cg-RX-API-DMAC10.html
Inventor
シェア,マシュー,ディー.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2014515354A publication Critical patent/JP2014515354A/ja
Publication of JP2014515354A5 publication Critical patent/JP2014515354A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014511580A 2011-05-19 2012-05-18 Osw−1類似体および抱合体、ならびにそれらの使用 Pending JP2014515354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488023P 2011-05-19 2011-05-19
US61/488,023 2011-05-19
PCT/US2012/038562 WO2012159027A2 (en) 2011-05-19 2012-05-18 Osw-1 analogs and conjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2014515354A true JP2014515354A (ja) 2014-06-30
JP2014515354A5 JP2014515354A5 (cg-RX-API-DMAC10.html) 2015-07-09

Family

ID=47177654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511580A Pending JP2014515354A (ja) 2011-05-19 2012-05-18 Osw−1類似体および抱合体、ならびにそれらの使用

Country Status (5)

Country Link
US (1) US9790253B2 (cg-RX-API-DMAC10.html)
EP (1) EP2710024A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014515354A (cg-RX-API-DMAC10.html)
CN (1) CN103857689A (cg-RX-API-DMAC10.html)
WO (1) WO2012159027A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056236A (zh) * 2015-08-13 2015-11-18 暨南大学 Orp4l在制备治疗急性髓性白血病产品中的应用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN111159770B (zh) * 2019-12-31 2022-12-13 医渡云(北京)技术有限公司 文本数据脱敏方法、装置、介质及电子设备
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
FR3125047B1 (fr) * 2021-07-06 2024-03-15 Centre Nat Rech Scient Composé de type 7a,8,9,10,11,11a-hexahydro-1H,7H-pyrano[2,3-c]xanthene, leur procédé de préparation, leurs intermédiaires et leurs applications thérapeutiques.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948794A (ja) * 1995-06-02 1997-02-18 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US20030069214A1 (en) * 2001-08-07 2003-04-10 Zhendong Jin Process for preparing saponin compounds
CN1844138A (zh) * 2006-05-12 2006-10-11 中国科学院上海有机化学研究所 一种合成虎眼万年青皂甙的脱除保护基的方法
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318924A1 (de) 1993-06-03 1994-12-08 Schering Ag Cephalostatin-Analoga
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20050004044A1 (en) 2003-04-07 2005-01-06 Board Of Regents Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7358377B2 (en) 2004-03-29 2008-04-15 University Of Iowa Research Foundation Schweinfurthin analogues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948794A (ja) * 1995-06-02 1997-02-18 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US20030069214A1 (en) * 2001-08-07 2003-04-10 Zhendong Jin Process for preparing saponin compounds
CN1844138A (zh) * 2006-05-12 2006-10-11 中国科学院上海有机化学研究所 一种合成虎眼万年青皂甙的脱除保护基的方法
WO2010068877A2 (en) * 2008-12-11 2010-06-17 President And Fellows Of Harvard College Compounds that bind oxysterol binding proteins, and methods of use thereof

Also Published As

Publication number Publication date
WO2012159027A3 (en) 2013-03-28
EP2710024A4 (en) 2015-04-29
WO2012159027A2 (en) 2012-11-22
US20140135279A1 (en) 2014-05-15
CN103857689A (zh) 2014-06-11
US9790253B2 (en) 2017-10-17
EP2710024A2 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
KR102692309B1 (ko) Fxr (nr1h4) 조정 화합물
Sepe et al. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)
AU2021269433A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
JP6300730B2 (ja) ベツリンの誘導体
JP7021080B2 (ja) ファルネソイドx受容体調節剤
US9790253B2 (en) OSW-1 analogs and conjugates, and uses thereof
CN104910238B (zh) 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途
KR20190017027A (ko) Fxr (nr1h4) 조정 화합물
CN100526328C (zh) 17β-羟基类固醇脱氢酶抑制剂
WO2012013816A1 (en) Compounds and methods for treating neoplasia
CA3022327C (en) INDAZOLE SYNTHESIS
EP2499151A2 (en) Mammalian metabolites of steroids
Fan et al. Design, synthesis, and biological evaluation of a novel indoleamine 2, 3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
WO2021150885A1 (en) Cannabinoid derivatives
CN115715201A (zh) 葡萄糖雷公藤甲素缀合物及其用途
Ge et al. New cinnamic acid-pregenolone hybrids as potential antiproliferative agents: Design, synthesis and biological evaluation
WO2019196953A1 (en) Ntcp inhibitors
Pettit et al. Antineoplastic agents. 606. The betulastatins
KR20260041688A (ko) Gpx4 억제제 및 세놀리틱 화합물 및 이의 용도
US20210292326A1 (en) Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same
NL2031175B1 (en) Dhcr24 inhibitory compounds
KR20240125979A (ko) 에폭시 스테로이드
ES2312965T3 (es) Sulfamatos de d-homoestra-1,3,5(10)-trien-3-il-2-sustituidos con efectos antitumoral.
US20110319352A1 (en) Compounds That Bind Oxysterol Binding Proteins, and Methods of Use Thereof
Nunez The Ligand Binding Properties of the Oxysterol-binding Protein Family Subfamily-I

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170328